Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?

ctDNA monitoring during PARP-inhibitor maintenance in ovarian cancer, discussing whether it can further personalize treatment.

Gynecol OncolPubMed 41252813DOI 10.1016/j.ygyno.2025.11.005